Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / GPR65

GPR65

Basics

Aliases:
This biomarker is also known as:
  • G protein-coupled receptor 65,
  • Q8IYL9,
  • G-protein coupled receptor 65,
  • T-cell death-associated gene 8 protein,
  • hTDAG8,
  • TDAG8,
  • psychosine receptor,

View in BioMuta

Description…

GPR65, a member of the G-protein coupled receptor 1 family, is a receptor for the glycosphingolipid psychosine (PSY) and several related glycosphingolipids. GPR65 may have a role in activation-induced cell death or differentiation of T-cells. It is expressed in thymus, spleen, lymph nodes, small intestine, lung, placenta and peripheral blood leukocytes.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: GPR65

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Two
QA State: Under Review

Overview

No additional ovarian data available.

Performance Comment

GPR65 was one of 50 tumor vasculature-associated genes with transmembrane or secreted protein products identified through expression profiling of ovarian cancer vascular cells. These 50 tumor vascular markers (TVMs) also had low or no expression in normal tissues. GPR65 was not in the group of 13 selected for further validation.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 11/20/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.